Major corporations are reshaping their product lines and marketing strategies to capitalize on the massive behavioral shifts driven by GLP-1 weight-loss drugs, signaling a fundamental change in American consumer habits that could reach $150 billion by 2035.
Story Highlights
- Target is expanding protein and supplement shelf space in 2026 to meet GLP-1 user demand
- The weight loss drug market is projected to reach $150 billion by 2035, with 30 million U.S. users
- Major brands like Nestlé, Conagra, and Danone are launching GLP-1-specific product lines
- Consumer demand is shifting toward high-protein, high-fiber foods and fitness equipment
Target Leads Corporate Pivot to GLP-1 Market
Target’s chief merchandising officer, Lisa Roath, revealed that the retailer is tracking cultural shifts and influencer trends to capitalize on changes in GLP-1-driven consumer behavior.
The company plans to expand shelf space in early 2026 specifically for protein bars and supplements, responding to what Roath describes as explosive growth in these categories. Target buyers now monitor social media feeds and cultural movements to anticipate purchasing patterns among the growing population of users of weight-loss medications.
Target beefs up protein, supplement offerings, capitalizing on weight loss drug trend https://t.co/zCp4zpVZKy
— FOX Business (@FoxBusiness) December 10, 2025
Massive Market Expansion Drives Business Strategy
Morgan Stanley projects that the U.S. weight-loss medication market will grow from 8 million current users to 30 million by 2035, representing 20-25% of the obese population and an $80 billion market opportunity.
This dramatic expansion explains why Target is seeing increased demand across multiple categories beyond food, including athletic wear and home fitness equipment. The behavioral changes extend far beyond dietary habits, creating new revenue streams in the apparel and fitness sectors as consumers adopt more active lifestyles.
Corporate Giants Launch Targeted Product Lines
Nestlé Health Science launched a comprehensive platform offering personalized care for GLP-1 users, focusing on preserving lean muscle mass and managing digestive issues common with these medications. Conagra Brands introduced an “on track” badge system to identify high-protein, low-calorie products suitable for users of weight-loss medicines.
Danone North America created Oikos Fusion yogurt, specifically marketed to support muscle maintenance and digestive health for GLP-1 users, making it the first yogurt designed for this growing demographic.
Economic Implications Signal Major Market Shift
The rapid adoption of diabetes medications repurposed for weight loss demonstrates how pharmaceutical breakthroughs can create entirely new consumer markets. Companies are positioning themselves at the “tip of the iceberg” of behavioral changes, as Target’s Roath puts it. This corporate response reflects a smart business strategy that capitalizes on documented consumer needs rather than speculative trends.
The focus on protein supplementation addresses legitimate nutritional deficiencies caused by appetite suppression, showing companies are responding to fundamental health concerns while building profitable product lines.
